See more : Zosano Pharma Corporation (ZSANQ) Income Statement Analysis – Financial Results
Complete financial analysis of NextCure, Inc. (NXTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NextCure, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Monash IVF Group Limited (MVF.AX) Income Statement Analysis – Financial Results
- Narbada Gems and Jewellery Limited (NARBADA.BO) Income Statement Analysis – Financial Results
- HK Asia Holdings Limited (1723.HK) Income Statement Analysis – Financial Results
- Zhejiang Natural Outdoor Goods Inc. (605080.SS) Income Statement Analysis – Financial Results
- BNY Mellon Strategic Municipals, Inc. (LEO) Income Statement Analysis – Financial Results
NextCure, Inc. (NXTC)
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 22.38M | 6.35M | 0.00 | 0.00 |
| Cost of Revenue | 3.68M | 4.48M | 4.30M | 46.55K | 34.22K | 1.68M | 582.00K |
| Gross Profit | -3.68M | -4.48M | -4.30M | 22.33M | 6.31M | -1.68M | -582.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.79% | 99.46% | 0.00% | 0.00% |
| Research & Development | 47.93M | 54.20M | 50.19M | 46.55M | 34.22M | 19.79M | 12.95M |
| General & Administrative | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.71M | 21.71M | 20.57M | 17.05M | 9.61M | 3.41M | 2.60M |
| Other Expenses | 0.00 | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Operating Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Cost & Expenses | 67.64M | 75.91M | 70.77M | 63.60M | 43.83M | 23.20M | 15.55M |
| Interest Income | 0.00 | 1.17M | 1.32K | 4.55K | 3.75K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 77.00K | 183.00K | 209.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 3.68M | 4.48M | 4.30M | 3.41M | 2.69M | 1.68M | 582.00K |
| EBITDA | -59.04M | -70.25M | -65.01M | -37.81M | -34.79M | -21.10M | -14.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -548.20% | 0.00% | 0.00% |
| Operating Income | -67.64M | -75.91M | -70.77M | -41.23M | -37.48M | -23.20M | -15.55M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -184.22% | -590.55% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.91M | 1.18M | 1.38M | 4.62M | 3.75M | 397.00K | 80.00K |
| Income Before Tax | -62.72M | -74.73M | -69.39M | -36.60M | -33.74M | -22.80M | -15.47M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -163.57% | -531.54% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -5.30M | 6.96M | -3.41M | 2.52M | 397.00K | 0.00 |
| Net Income | -62.72M | -69.43M | -69.39M | -33.19M | -33.74M | -22.80M | -15.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -148.32% | -531.54% | 0.00% | 0.00% |
| EPS | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| EPS Diluted | -2.25 | -2.50 | -2.51 | -1.21 | -2.15 | -2.27 | -1.54 |
| Weighted Avg Shares Out | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
| Weighted Avg Shares Out (Dil) | 27.84M | 27.74M | 27.62M | 27.53M | 15.70M | 10.04M | 10.04M |
NextCure Provides Year-End Clinical Pipeline Updates
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Disease
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
Source: https://incomestatements.info
Category: Stock Reports